Skip to main content
eScholarship
Open Access Publications from the University of California

PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations.

  • Author(s): Pharoah, Paul DP
  • Song, Honglin
  • Dicks, Ed
  • Intermaggio, Maria P
  • Harrington, Patricia
  • Baynes, Caroline
  • Alsop, Kathryn
  • Australian Ovarian Cancer Study Group
  • Bogdanova, Natalia
  • Cicek, Mine S
  • Cunningham, Julie M
  • Fridley, Brooke L
  • Gentry-Maharaj, Aleksandra
  • Hillemanns, Peter
  • Lele, Shashi
  • Lester, Jenny
  • McGuire, Valerie
  • Moysich, Kirsten B
  • Poblete, Samantha
  • Sieh, Weiva
  • Sucheston-Campbell, Lara
  • Widschwendter, Martin
  • Ovarian Cancer Association Consortium
  • Whittemore, Alice S
  • Dörk, Thilo
  • Menon, Usha
  • Odunsi, Kunle
  • Goode, Ellen L
  • Karlan, Beth Y
  • Bowtell, David D
  • Gayther, Simon A
  • Ramus, Susan J
  • et al.

Published Web Location

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072371/pdf/djv347.pdf
No data is associated with this publication.
Abstract

Mosaic truncating mutations in the protein phosphatase, Mg(2+)/Mn(2+)-dependent, 1D (PPM1D) gene have recently been reported with a statistically significantly greater frequency in lymphocyte DNA from ovarian cancer case patients compared with unaffected control patients. Using massively parallel sequencing (MPS) we identified truncating PPM1D mutations in 12 of 3236 epithelial ovarian cancer (EOC) case patients (0.37%) but in only one of 3431 unaffected control patients (0.03%) (P = .001). All statistical tests were two-sided. A combination of Sanger sequencing, pyrosequencing, and MPS data suggested that 12 of the 13 mutations were mosaic. All mutations were identified in post-chemotherapy treatment blood samples from case patients (n = 1827) (average 1234 days post-treatment in carriers) rather than from cases collected pretreatment (less than 14 days after diagnosis, n = 1384) (P = .002). These data suggest that PPM1D variants in EOC cases are primarily somatic mosaic mutations caused by treatment and are not associated with germline predisposition to EOC.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Item not freely available? Link broken?
Report a problem accessing this item